NO20003674L - Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase - Google Patents

Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase

Info

Publication number
NO20003674L
NO20003674L NO20003674A NO20003674A NO20003674L NO 20003674 L NO20003674 L NO 20003674L NO 20003674 A NO20003674 A NO 20003674A NO 20003674 A NO20003674 A NO 20003674A NO 20003674 L NO20003674 L NO 20003674L
Authority
NO
Norway
Prior art keywords
treatment
oral administration
solid pharmaceutical
leishmaniase
phosin
Prior art date
Application number
NO20003674A
Other languages
English (en)
Norwegian (no)
Other versions
NO20003674D0 (no
Inventor
Juergen Engel
Werner Sarlikiotis
Thomas Klenner
Peter Hilgard
Dieter Sauerbier
Eckhard Milsmann
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Priority to NO20003674A priority Critical patent/NO20003674L/no
Publication of NO20003674D0 publication Critical patent/NO20003674D0/no
Publication of NO20003674L publication Critical patent/NO20003674L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20003674A 1998-01-22 2000-07-18 Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase NO20003674L (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20003674A NO20003674L (no) 1998-01-22 2000-07-18 Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP1998/000345 WO1999037289A1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
NO20003674A NO20003674L (no) 1998-01-22 2000-07-18 Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase

Publications (2)

Publication Number Publication Date
NO20003674D0 NO20003674D0 (no) 2000-07-18
NO20003674L true NO20003674L (no) 2000-07-18

Family

ID=8166843

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003674A NO20003674L (no) 1998-01-22 2000-07-18 Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase

Country Status (24)

Country Link
US (1) US6544551B1 (hu)
EP (1) EP1051159B1 (hu)
JP (1) JP2002501015A (hu)
KR (1) KR100517399B1 (hu)
CN (1) CN100413492C (hu)
AT (1) ATE215817T1 (hu)
AU (1) AU756805B2 (hu)
BR (1) BR9814772A (hu)
CA (1) CA2318260C (hu)
CZ (1) CZ299229B6 (hu)
DE (1) DE69804865T2 (hu)
DK (1) DK1051159T3 (hu)
ES (1) ES2175663T3 (hu)
HU (1) HUP0004363A3 (hu)
IL (1) IL136196A (hu)
NO (1) NO20003674L (hu)
NZ (1) NZ505648A (hu)
PL (1) PL189654B1 (hu)
PT (1) PT1051159E (hu)
SI (1) SI1051159T1 (hu)
SK (1) SK284839B6 (hu)
TR (1) TR200001717T2 (hu)
UA (1) UA68372C2 (hu)
WO (1) WO1999037289A1 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
WO2003090757A1 (en) * 2002-04-26 2003-11-06 Rudolf Perl Pharmaceutical compositions of phospholipid derivatives
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
PT1545553E (pt) 2002-07-30 2011-09-12 Aeterna Zentaris Gmbh Utilização de alquilfosfocolinas em combinação com medicamentos antitumorais
PL1663197T3 (pl) 2003-09-09 2008-09-30 Biogen Idec Int Gmbh Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy
DE202005022112U1 (de) 2004-10-08 2014-04-24 Forward Pharma A/S Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, umfassend einen Fumarsaureester
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
CA2794513A1 (en) 2010-03-31 2011-10-06 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
US9358244B2 (en) 2010-11-22 2016-06-07 Oblita Therapeutics Bvba Solid dosage forms of oleyl phosphocholine
EP3616701A1 (en) 2011-06-24 2020-03-04 GRI Bio, Inc. Prevention and treatment of inflammatory conditions
WO2014166941A1 (en) * 2013-04-08 2014-10-16 Academisch Medisch Centrum Miltefosin or perifosin for use in the treatment of ibd
KR102193599B1 (ko) 2014-09-17 2020-12-21 스티어라이프 인디아 프라이빗 리미티드 발포성 조성물 및 이의 제조방법
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法
WO2017098481A1 (en) 2015-12-12 2017-06-15 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
EP3965739B1 (en) * 2019-04-12 2024-07-10 Oblita Therapeutics BVBA Tablet dosage formulations of oleyl phosphocholine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
CA1280369C (en) * 1985-12-04 1991-02-19 Hansjorg Eibl Pharmaceutical with anti-tumor effect
US4762658A (en) * 1986-10-08 1988-08-09 Central Soya Company, Inc. Method of tableting of de-oiled phosphatides (lecithin)
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
EP0916343A1 (de) * 1989-09-27 1999-05-19 ASTA Medica Aktiengesellschaft Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Also Published As

Publication number Publication date
NO20003674D0 (no) 2000-07-18
IL136196A0 (en) 2001-05-20
KR100517399B1 (ko) 2005-09-28
PL189654B1 (pl) 2005-09-30
US6544551B1 (en) 2003-04-08
HUP0004363A3 (en) 2002-12-28
CZ20002596A3 (cs) 2000-10-11
ES2175663T3 (es) 2002-11-16
SK284839B6 (sk) 2005-12-01
CA2318260A1 (en) 1999-07-29
DE69804865D1 (de) 2002-05-16
JP2002501015A (ja) 2002-01-15
CN1283111A (zh) 2001-02-07
HUP0004363A2 (hu) 2001-04-28
TR200001717T2 (tr) 2000-11-21
EP1051159B1 (en) 2002-04-10
AU756805B2 (en) 2003-01-23
SI1051159T1 (en) 2002-10-31
AU6212198A (en) 1999-08-09
DK1051159T3 (da) 2002-08-05
UA68372C2 (en) 2004-08-16
ATE215817T1 (de) 2002-04-15
DE69804865T2 (de) 2002-11-07
IL136196A (en) 2004-07-25
PL342838A1 (en) 2001-07-16
CN100413492C (zh) 2008-08-27
WO1999037289A1 (en) 1999-07-29
KR20010034311A (ko) 2001-04-25
BR9814772A (pt) 2000-10-24
PT1051159E (pt) 2002-09-30
EP1051159A1 (en) 2000-11-15
CA2318260C (en) 2006-11-21
SK9862000A3 (en) 2000-11-07
NZ505648A (en) 2002-10-25
CZ299229B6 (cs) 2008-05-21

Similar Documents

Publication Publication Date Title
NO20003674D0 (no) Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase
EP1049459A4 (en) ORAL LIQUID COMPOSITIONS
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
PL334566A1 (en) Treatment of sclerosis multiplex by oral and inhalatory administration of a copolymer-1
FR2714830B1 (fr) Composition contenant des acides nucléiques, préparation et utilisations.
ATE329897T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
HUP9903906A2 (hu) Kelátképző clioquinol felhasználása Alzheimer-kór kezelésére alkalmas gyógyszerkészítmények előállításánál
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
BG105173A (en) Novel salt form of pantoprazole
HUP0301349A2 (hu) IL-11-tartalmú készítmények
DE69034226D1 (de) Herstellungsverfahren von Huperzine A und deren Analogen und Verbindungen nützlich dazu
NZ320355A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
TR200101083T2 (tr) (7alfa,17alfa)-17-hidroksi- 7-metil-19-nor-17-pregn-5 (10)-en-20-in-3-on içeren yüksek saflıkta bileşim.
UA74388C2 (uk) Фармацевтичні композиції тизоксаніду і нітазоксаніду
BG104424A (en) Pseudopolymorphic forms of 2-[2-[4-[bis(4-fluorophenyl) methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride
SE8006550L (sv) Farmakologisk komposition, samt sett for dess framstellning
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
BG104673A (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
UA32939A (uk) Сульфокамфокаїн, спосіб його виготовлення і спосіб підготовки обладнання для виготовлення сульфокамфокаїну
AU5662996A (en) Compounds and compositions for delivering active agents
UA30798A (uk) Спосіб пролонгованої терапії онкологічних хворих
YU87302A (sh) Inhibitori 11-beta-hidroksi steroidne dehidrogenaze, tip 1

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application